Outsourcing

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Articles

CMOs are working hard to improve performance by investigating new technologies for filtration and purification.

Downstream Processing Continues to Worry CMOs

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Bio/pharma companies that are qualifying potential contract service providers should investigate post-merger integration activities and capital structure as part of the due diligence.

Potential Consequences of the CDMO Acquisition Binge

CDMOs need to be aware that unfavorable public markets put emerging bio/pharma R&D spending at risk in 2017.

Bio/Pharma Funding Challenges Could Hurt CDMOs in 2017

Acquisition binges often lead to hangovers; here’s what to watch out for.

Watch Out for the Hangover

Growth may be slowing, but outsourcing activity remains healthy.

Outsourcing of Biomanufacturing in 2016

Demand is driving expansion and consolidation of formulation and clinical trial materials services.

CMC Development is Hot

Global economic and political uncertainty could slow bio/pharma development activity.

Global Conflicts and CMO Impacts

Susan Haigney is lead editor of Pharmaceutical Technology and Pharmaceutical Technology Europe.

The pharma outsourcing market starts 2016 with expansions, acquisitions, and new offerings.

Pharma Outsourcing Market Expands

Heightened global uncertainty could slow bio/pharma development activity.Bio/pharmaceutical companies, and the companies that serve them, tend to think they are immune from broader macroeconomic and political developments. As populations age, emerging middle classes expand, and scientific knowledge progresses, research on new drugs and demand for new therapies seem to follow an inexorably upward trend.

Macro Matters

Industry experts discuss what the outsourcing market holds for 2016.

Outsourcing Outlook